



[Updated]

11 Oct 2022

Dear Healthcare Professionals,

Subject: Safety Information Update on Otsuka Pharmaceutical Products

At Otsuka, patient safety is our utmost priority. As such, we endeavor to provide the latest prescribing information to the local medical community to assist in the best practice and to foster safe use of medicines.

We would like to inform you that we have been recently granted the regulatory approval for the upcoming version of the package insert of the following products, which contains updated safety information:

Product name: ABILIFY TABLETS 2MG (HK-62721)
ABILIFY TAB 5MG (HK-55787)
ABILIFY TAB 10MG (HK-53327)
ABILIFY TAB 15MG (HK-53326)
ABILIFY DISCMELT ORALLY DISINTEGRATING TAB 10MG (HK-59639)
ABILIFY DISCMELT ORALLY DISINTEGRATING TAB 15MG (HK-59638)
Version Date: September 2022

If you are interested in knowing further about these safety information changes prior to the print of the package insert in the sales pack, please do not hesitate to contact our PV Department.

Thank you for your attention and your continued support of Otsuka products.

Yours sincerely,
PV Department
Otsuka Pharmaceutical (H.K.) Limited

Disclaimer: This Dear HCP Letter is meant for communicating to the medical practitioner about the upcoming safety changes to be appeared in the package insert of Otsuka products concerned. Its sole purpose is to facilitate scientific, non-promotional communication.